All Posts

What if I told you the pharma industry losing $250B in revenue wasn’t a crisis—but a success? The patent cliff is back in the headlines. I believe it’s being widely misunderstood—and that the real problem lies elsewhere.

NíoSync is proud to announce our strategic partnership with Uniphar, accelerating access to life-changing therapies for patients across Europe. NíoSync is building Europe’s leading commercialisation platform for specialty biopharmaceutical products, designed to ensure that medical innovation reaches patients fairly, efficiently and at scale. Through this collaboration, NíoSync gains immediate access to Uniphar Group's pan-European commercial infrastructure, accelerating the d

Despite Europe’s reputation for scientific leadership, the truth is that patients across the continent are waiting longer, and often in...

Ireland's biopharma sector is a world-class success story, but what worked in the past will not lead to future success. We've spent...

Last week, President Trump announced a “Most Favored Nation” policy that would force pharma companies to give the U.S. the lowest global...